Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisolone; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PROTEUS
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
31 May 2026 Results published in the Media Release
31 May 2026 According to Dana-Farber research institute media release, data from this study published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com